Altimmune Q3 revenue beats expectations

Reuters

Nov 06

Altimmune Q3 revenue beats expectations

Overview

Altimmune Q3 revenue and net income beat analyst expectations
Adjusted EPS for Q3 beats consensus, reflecting improved financial performance
Company strengthens executive team with key appointments

Outlook

Altimmune expects 48-week data from Phase 2b IMPACT trial in Q4 2025
Company to hold End-of-Phase 2 meeting with FDA in Q4 2025
Topline results from RECLAIM trial in AUD expected in 2026

Result Drivers

Research and development expenses were $15.0 million for the three months ended September 30, 2025, compared to $19.8 million in the same period in 2024

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Revenue	Beat	$5,000	$600 (8 Analysts)
Q3 EPS	Beat	-$0.21	-$0.27 (9 Analysts)
Q3 Net Income	Beat	-$19.01 mln	-$23.60 mln (8 Analysts)
Q3 Income from Operations	Beat	-$20.86 mln	-$25.50 mln (8 Analysts)
Q3 Basic EPS		-$0.21
Q3 Operating Expenses		$20.86 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Altimmune Inc is $18.00, about 79.2% above its November 5 closing price of $3.75

Press Release: ID:nGNX21Cg96

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2581062060"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581062060\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581062060?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 20:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581062060","market":"fut","top_or_hot":-1,"title":"Altimmune Q3 revenue beats expectations","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Altimmune Q3 revenue beats expectations</title></head><body><p><span>Overview</span></p><ul><li><p>Altimmune Q3 revenue and net income beat analyst expectations</p></li><li><p>Adjusted EPS for Q3 beats consensus, reflecting improved financial performance</p></li><li><p>Company strengthens executive team with key appointments</p></li></ul><p><span>Outlook</span></p><ul><li><p>Altimmune expects 48-week data from Phase 2b IMPACT trial in Q4 2025</p></li><li><p>Company to hold End-of-Phase 2 meeting with FDA in Q4 2025</p></li><li><p>Topline results from RECLAIM trial in AUD expected in 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>Research and development expenses were $15.0 million for the three months ended September 30, 2025, compared to $19.8 million in the same period in 2024</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td><p>Beat</p></td><td><p>$5,000</p></td><td><p>$600 (8 Analysts)</p></td></tr><tr><td><p>Q3 EPS</p></td><td><p>Beat</p></td><td><p>-$0.21</p></td><td><p>-$0.27 (9 Analysts)</p></td></tr><tr><td><p>Q3 Net Income</p></td><td><p>Beat</p></td><td><p>-$19.01 mln</p></td><td><p>-$23.60 mln (8 Analysts)</p></td></tr><tr><td><p>Q3 Income from Operations</p></td><td><p>Beat</p></td><td><p>-$20.86 mln</p></td><td><p>-$25.50 mln (8 Analysts)</p></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.21</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$20.86 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 8 \"strong buy\" or \"buy\", 1 \"hold\" and 1 \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Altimmune Inc is $18.00, about 79.2% above its November 5 closing price of $3.75</p></li></ul><p>Press Release: <span>ID:nGNX21Cg96</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Altimmune Q3 revenue beats expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAltimmune Q3 revenue beats expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-06 20:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Altimmune Q3 revenue beats expectations</title></head><body><p><span>Overview</span></p><ul><li><p>Altimmune Q3 revenue and net income beat analyst expectations</p></li><li><p>Adjusted EPS for Q3 beats consensus, reflecting improved financial performance</p></li><li><p>Company strengthens executive team with key appointments</p></li></ul><p><span>Outlook</span></p><ul><li><p>Altimmune expects 48-week data from Phase 2b IMPACT trial in Q4 2025</p></li><li><p>Company to hold End-of-Phase 2 meeting with FDA in Q4 2025</p></li><li><p>Topline results from RECLAIM trial in AUD expected in 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>Research and development expenses were $15.0 million for the three months ended September 30, 2025, compared to $19.8 million in the same period in 2024</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td><p>Beat</p></td><td><p>$5,000</p></td><td><p>$600 (8 Analysts)</p></td></tr><tr><td><p>Q3 EPS</p></td><td><p>Beat</p></td><td><p>-$0.21</p></td><td><p>-$0.27 (9 Analysts)</p></td></tr><tr><td><p>Q3 Net Income</p></td><td><p>Beat</p></td><td><p>-$19.01 mln</p></td><td><p>-$23.60 mln (8 Analysts)</p></td></tr><tr><td><p>Q3 Income from Operations</p></td><td><p>Beat</p></td><td><p>-$20.86 mln</p></td><td><p>-$25.50 mln (8 Analysts)</p></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.21</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$20.86 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 8 \"strong buy\" or \"buy\", 1 \"hold\" and 1 \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Altimmune Inc is $18.00, about 79.2% above its November 5 closing price of $3.75</p></li></ul><p>Press Release: <span>ID:nGNX21Cg96</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALT","symbol_name":"Altimmune, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI0LN:1","article_id":"2581062060","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581062060","pubTimestamp":1762431061,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Altimmune Q3 revenue beats expectationsOverviewAltimmune Q3 revenue and net income beat analyst expectationsAdjusted EPS for Q3 beats consensus, reflecting improved financial performanceCompany streng","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALT":"Altimmune, Inc.","BK4599":"减肥药","LU1878469433.USD":"THREADNEEDLE (LUX) - AMERICAN SMALLER COMPANIES \"A\" (USD) ACC","BK4139":"生物科技"},"translate_title":"Altimmune第三季度收入超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALT":0.9},"content_text":"Altimmune Q3 revenue beats expectationsOverviewAltimmune Q3 revenue and net income beat analyst expectationsAdjusted EPS for Q3 beats consensus, reflecting improved financial performanceCompany strengthens executive team with key appointmentsOutlookAltimmune expects 48-week data from Phase 2b IMPACT trial in Q4 2025Company to hold End-of-Phase 2 meeting with FDA in Q4 2025Topline results from RECLAIM trial in AUD expected in 2026Result DriversResearch and development expenses were $15.0 million for the three months ended September 30, 2025, compared to $19.8 million in the same period in 2024Key DetailsMetricBeat/MissActualConsensus EstimateQ3 RevenueBeat$5,000$600 (8 Analysts)Q3 EPSBeat-$0.21-$0.27 (9 Analysts)Q3 Net IncomeBeat-$19.01 mln-$23.60 mln (8 Analysts)Q3 Income from OperationsBeat-$20.86 mln-$25.50 mln (8 Analysts)Q3 Basic EPS-$0.21Q3 Operating Expenses$20.86 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 8 \"strong buy\" or \"buy\", 1 \"hold\" and 1 \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Altimmune Inc is $18.00, about 79.2% above its November 5 closing price of $3.75Press Release: ID:nGNX21Cg96For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}